Oren Livnat
Stock Analyst at HC Wainwright & Co.
(2.22)
# 1,216
Out of 4,650 analysts
128
Total ratings
36.84%
Success rate
-1.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Reiterates: Buy | $6 | $3.18 | +88.68% | 2 | Oct 22, 2024 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $27 | $12.80 | +110.94% | 12 | Oct 21, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $8.05 | +148.45% | 7 | Sep 30, 2024 | |
| ACST Acasti Pharma | Reiterates: Buy | $12 | $3.37 | +256.08% | 2 | Sep 26, 2024 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $57.97 | +62.17% | 10 | Sep 17, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $47 → $50 | $35.13 | +42.33% | 8 | Sep 5, 2024 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6 | $3.23 | +85.76% | 9 | Aug 15, 2024 | |
| PCRX Pacira BioSciences | Maintains: Buy | $57 → $39 | $17.13 | +127.67% | 17 | Aug 12, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $200 | $111.37 | +79.58% | 15 | Aug 1, 2024 | |
| CARA Cara Therapeutics | Downgrades: Neutral | n/a | $0.27 | - | 13 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $1.56 | +797.44% | 10 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $61 | $39.67 | +53.77% | 8 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $6.82 | +9.97% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $1.42 | +463.38% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $5.55 | +972.07% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $2.84 | +6,871.83% | 2 | May 7, 2021 |
Trevi Therapeutics
Oct 22, 2024
Reiterates: Buy
Price Target: $6
Current: $3.18
Upside: +88.68%
Avadel Pharmaceuticals
Oct 21, 2024
Reiterates: Buy
Price Target: $27
Current: $12.80
Upside: +110.94%
Zevra Therapeutics
Sep 30, 2024
Reiterates: Buy
Price Target: $20
Current: $8.05
Upside: +148.45%
Acasti Pharma
Sep 26, 2024
Reiterates: Buy
Price Target: $12
Current: $3.37
Upside: +256.08%
ANI Pharmaceuticals
Sep 17, 2024
Reiterates: Buy
Price Target: $94
Current: $57.97
Upside: +62.17%
Collegium Pharmaceutical
Sep 5, 2024
Maintains: Buy
Price Target: $47 → $50
Current: $35.13
Upside: +42.33%
Xeris Biopharma Holdings
Aug 15, 2024
Reiterates: Buy
Price Target: $6
Current: $3.23
Upside: +85.76%
Pacira BioSciences
Aug 12, 2024
Maintains: Buy
Price Target: $57 → $39
Current: $17.13
Upside: +127.67%
Jazz Pharmaceuticals
Aug 1, 2024
Reiterates: Buy
Price Target: $200
Current: $111.37
Upside: +79.58%
Cara Therapeutics
Jun 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.27
Upside: -
May 14, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $1.56
Upside: +797.44%
May 13, 2024
Maintains: Buy
Price Target: $57 → $61
Current: $39.67
Upside: +53.77%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $6.82
Upside: +9.97%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $1.42
Upside: +463.38%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $5.55
Upside: +972.07%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $2.84
Upside: +6,871.83%